News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Inc. Ensuring That Products - Aricept(R), Aciphex(R) And Zonegran(R) - Remain Available To All Patients


10/19/2005 5:12:20 PM

TEANECK, N.J., Jan. 14 /PRNewswire/ -- Eisai Inc. today announced that Cardinal Health will no longer serve as a distributor of record for Eisai's US pharmaceutical products as the companies did not reach agreement regarding distribution services. Eisai is actively alerting health care professionals and consumers, and is working to transition pharmacy customers to its many other distributors, to avoid potential treatment disruption for patients who benefit from treatment with Aricept(R) (donepezil HCl tablets), Aciphex(R) (rabeprazole sodium) and Zonegran(R) (zonisamide).

Eisai remains committed to its human health care mission to satisfy unmet medical needs for patients and their families, such as with Aricept(R), the number-one prescribed Alzheimer's disease therapy worldwide. "Ensuring a stable supply of and access to high-quality products is an important priority as the pharmaceuticals manufactured by Eisai can directly impact the lives of patients and their loved ones," says Lonnel Coats, President and COO of Eisai Inc. "The public has our commitment that ample supplies of these important prescription products will be available through the distributors that serve a vital role in supplying pharmacy providers with the products that patients need."

Eisai Inc. is a US pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets products in more than 30 countries. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated and successful pharmaceutical company that focuses its efforts in four therapeutic areas: neurology, gastrointestinal disorders, oncology and critical care. The company employs more than 1,100 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation R&D facility in Research Triangle Park, NC, and in the field.

Information About Aricept(R) (donepezil HCl tablets) Treatment in Alzheimer's Disease

While there is no cure for Alzheimer's disease, medical treatments are available to manage symptoms of the disease. Once-a-day prescription Aricept(R) is indicated for mild to moderate Alzheimer's disease. Aricept(R) is copromoted in the United States by Eisai Inc. and Pfizer Inc.

Aricept(R) is well tolerated but may not be for everyone. People at risk for stomach ulcers or who take certain other medicines should tell their doctors because serious stomach problems, such as bleeding, may get worse.

Some people may have nausea, diarrhea, not sleep well or vomit. Some people may have muscle cramps, feel very tired, or may not want to eat. In studies, these side effects were usually mild and went away over time. Some people who take Aricept(R) (donepezil HCl tablets) may experience fainting.

For full prescribing information on Aricept(R), please visit http://www.aricept.com/. For a listing of Eisai Inc. distributors of record, please visit http://www.eisai.com/.

Aricept is a registered trademark of Eisai Co., Ltd., Tokyo, Japan. Aricept(R) is copromoted in the US with Pfizer Inc.

Aciphex is a registered trademark of Eisai Co., Ltd., Tokyo, Japan. Aciphex(R) is copromoted in the US with Janssen Pharmaceutica Inc.

Zonegran is a registered trademark of Dainippon Pharmaceutical Co., Ltd., Osaka, Japan, and licensed exclusively to Eisai Inc.

Eisai Inc.

CONTACT: Cathy Pollini of Eisai Inc., +1-201-287-2052; or Limor Gellerof Hill & Knowlton, +1-212-885-0601, for Eisai Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES